3-{1-[6-(4-Amino-3-methyl-5-nitro-phenoxy)-pyrimidin-4-yl]-piperidin-4-yl}-7-methoxy-1,3,4,5-tetrahydro-benzo[d][1,3]diazepin-2-one → 3-{1-[6-(3,4-Diamino-5-methyl-phenoxy)-pyrimidin-4-yl]-piperidin-4-yl}-7-methoxy-1,3,4,5-tetrahydro-benzo[d][1,3]diazepin-2-one

HRID 1846454노트

반응식

HRID 1846454 반응식
[NH2:1][C:2]1[C:34]([N+:35]([O-])=O)=[CH:33][C:5]([O:6][C:7]2[N:12]=[CH:11][N:10]=[C:9]([N:13]3[CH2:18][CH2:17][CH:16]([N:19]4[CH2:25][CH2:24][C:23]5[CH:26]=[C:27]([O:30][CH3:31])[CH:28]=[CH:29][C:22]=5[NH:21][C:20]4=[O:32])[CH2:15][CH2:14]3)[CH:8]=2)=[CH:4][C:3]=1[CH3:38]>CO.[Pd]>[NH2:35][C:34]1[CH:33]=[C:5]([CH:4]=[C:3]([CH3:38])[C:2]=1[NH2:1])[O:6][C:7]1[N:12]=[CH:11][N:10]=[C:9]([N:13]2[CH2:14][CH2:15][CH:16]([N:19]3[CH2:25][CH2:24][C:23]4[CH:26]=[C:27]([O:30][CH3:31])[CH:28]=[CH:29][C:22]=4[NH:21][C:20]3=[O:32])[CH2:17][CH2:18]2)[CH:8]=1

참가 물질

4

반응물 1

HCID 669782863-{1-[6-(4-Amino-3-methyl-5-nitro-phenoxy)-pyrimidin-4-yl]-piperidin-4-yl}-7-methoxy-1,3,4,5-tetrahydro-benzo[d][1,3]diazepin-2-one

생성물 1

HCID 669783753-{1-[6-(3,4-Diamino-5-methyl-phenoxy)-pyrimidin-4-yl]-piperidin-4-yl}-7-methoxy-1,3,4,5-tetrahydro-benzo[d][1,3]diazepin-2-one

시약·촉매·용매 2

HCID 23938Palladium촉매HCID 887Methanol용매

실험 절차

830 mg (1.60 mmol) 3-{1-[6-(4-amino-3-methyl-5-nitro-phenoxy)-pyrimidin-4-yl]-piperidin-4-yl}-7-methoxy-1,3,4,5-tetrahydro-benzo[d][1,3]diazepin-2-one in 20 mL MeOH were combined with 100 mg palladium on charcoal (Pd/C 10%) and hydrogenated for 8 h under a hydrogen atmosphere of 50 psi. After the catalyst had been removed by suction filtering, the filtrate was evaporated down and the residue was reacted further as the crude product.

후처리

  1. customAfter the catalyst had been removed by suction
  2. filtrationfiltering
  3. customthe filtrate was evaporated down
  4. customthe residue was reacted further as the crude product

출처 및 근거

ORD 기록
ord-5a88f4d80f294d96a095e5c13ebe3edf
출처 데이터셋
uspto-grants-2015_02
특허 번호
US08952014B2

반응 노트

불러오는 중…